Brought to you by 
Celgene licenses its d-methylphenidate to Novartis
20 Dec 2011
Executive Summary
In exchange for $10mm up front, milestones of up to $100mm, plus funding of development and marketing, Novartis has licensed worldwide rights, excluding Canada, to Celgene's Phase III Attenade (d-methylphenidate) for use in attention deficit/attention deficit hyperactivity disorders. Celgene retains manufacturing rights and all rights in oncology.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Chiral Chemistry
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene licenses its d-methylphenidate to Novartis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice